ProfileGDS5678 / 1444386_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 34% 34% 34% 35% 34% 35% 34% 34% 34% 33% 34% 34% 34% 34% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8185634
GSM967853U87-EV human glioblastoma xenograft - Control 22.779734
GSM967854U87-EV human glioblastoma xenograft - Control 32.7844334
GSM967855U87-EV human glioblastoma xenograft - Control 42.7481835
GSM967856U87-EV human glioblastoma xenograft - Control 52.7246234
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8802435
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.825434
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7593334
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.7465734
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7432333
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7667534
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.752534
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.7776734
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7730834